pyrazole has been researched along with glucagon in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Candelore, MR; Dallas-Yang, Q; Guo, J; Jiang, G; Liang, R; McCann, PE; Miller, C; Parmee, ER; Qureshi, SA; Shang, J; Tata, JR; Tong, X; Tota, LM; Vincent, SH; Wright, MJ; Xiong, Y; Xu, SS; Yang, X; Zhang, BB | 1 |
1 other study(ies) available for pyrazole and glucagon
| Article | Year |
|---|---|
Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes.
Topics: Animals; Area Under Curve; beta-Alanine; Blood Glucose; CHO Cells; Cricetinae; Cricetulus; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Dogs; Glucagon; Glucagon-Like Peptide-1 Receptor; Humans; Inhibitory Concentration 50; Macaca mulatta; Mice; Mice, Obese; Microsomes, Liver; Pyrazoles; Rats; Receptors, Gastrointestinal Hormone; Receptors, Glucagon; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; Receptors, Vasoactive Intestinal Peptide, Type II; Receptors, Vasoactive Intestinal Polypeptide, Type I | 2012 |